Earnings and Growth Analysis : AzurRx BioPharma Stock Forecast, Price & News (NASDAQ:AZRX)

0
41

Earnings results for AzurRx BioPharma Stock Forecast, Price & News (NASDAQ:AZRX)

Estimate Momentum measures change in analyst sentiment over time and may be an indicator of future price movements. The Change in Consensus chart shows the current, 1 week ago, and 1 month ago consensus earnings per share (EPS*) forecasts. For the fiscal quarter endingJun 2020 , the consensus EPS* forecast has increased over the past week from -0.1 to -0.09(10.00%) and increased over the past month from -0.12 to -0.09(25.00%). Of the 2 analysts making quarterly forecasts, 2raised and none lowered their forecast. For the fiscal year ending Dec 2020 , the consensus EPS* forecast has increased over the past week from -0.5 to -0.49(2.00%) and remained the same over the past month at -0.5 . Of the 2 analysts making yearly forecasts, 1raised and 1 lowered their forecast.

AzurRx BioPharma last posted its earnings data on May 15th, 2020. The reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.11) by $0.09. AzurRx BioPharma has generated $0.00 earnings per share over the last year. AzurRx BioPharma has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Tuesday, August 18th, 2020 based off prior year’s report dates.

Analyst Opinion on AzurRx BioPharma Stock Forecast, Price & News (NASDAQ:AZRX)

3 Wall Street analysts have issued ratings and price targets for AzurRx BioPharma in the last 12 months. Their average twelve-month price target is $2.50, predicting that the stock has a possible upside of 165.96%. The high price target for AZRX is $3.00 and the low price target for AZRX is $2.00. There are currently 3 buy ratings for the stock, resulting in a consensus rating of “Buy.”

AzurRx BioPharma has received a consensus rating of Buy. The company’s average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings. According to analysts’ consensus price target of $2.50, AzurRx BioPharma has a forecasted upside of 166.0% from its current price of $0.94. AzurRx BioPharma has only been the subject of 2 research reports in the past 90 days.

Dividend Strength: AzurRx BioPharma Stock Forecast, Price & News (NASDAQ:AZRX)

AzurRx BioPharma does not currently pay a dividend. AzurRx BioPharma does not have a long track record of dividend growth.

Insiders buying/selling: AzurRx BioPharma Stock Forecast, Price & News (NASDAQ:AZRX)

In the past three months, AzurRx BioPharma insiders have not sold or bought any company stock. Only 7.00% of the stock of AzurRx BioPharma is held by insiders. Only 5.00% of the stock of AzurRx BioPharma is held by institutions.

Earnings and Valuation of AzurRx BioPharma Stock Forecast, Price & News (NASDAQ:AZRX

Earnings for AzurRx BioPharma are expected to grow in the coming year, from ($0.50) to ($0.42) per share. AzurRx BioPharma has a P/B Ratio of 5.53. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

More latest stories: here